MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
1.250
-0.060 (-4.58%)
Nov 6, 2026, 3:52 PM EST - Market open
MaxCyte Employees
MaxCyte had 91 employees as of December 31, 2025. The number of employees decreased by 23 or 20.18% compared to the previous year. That makes MaxCyte the 32,008th largest employer in the world and 4,138th in the United States.
Employees
91
Change (1Y)
-23
Growth (1Y)
-20.18%
Revenue / Employee
$341,220
Profits / Employee
-$391,604
Market Cap
129.01M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 91 | -23 | -20.18% |
| Dec 31, 2024 | 114 | -29 | -20.28% |
| Dec 31, 2023 | 143 | 18 | 14.40% |
| Dec 31, 2022 | 125 | 41 | 48.81% |
| Dec 31, 2021 | 84 | 19 | 29.23% |
| Mar 31, 2021 | 65 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Inogen | 753 |
| Neuronetics | 658 |
| RxSight | 461 |
| Quanterix | 450 |
| Pulmonx | 296 |
| Apyx Medical | 205 |
| Perspective Therapeutics | 166 |
| Nyxoah | 154 |
MXCT News
- 9 days ago - MaxCyte to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 23 days ago - MaxCyte reports preliminary Q3 revenue $8.1M, consensus $7.02M - TheFly
- 23 days ago - MaxCyte raises FY26 revenue view to $34M from $30M-$32M, consensus $31.45M - TheFly
- 23 days ago - MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance - GlobeNewsWire
- 6 weeks ago - MaxCyte appoints Kapileshwar as Chief Corporate Development Officer - TheFly
- 6 weeks ago - MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer - GlobeNewsWire
- 1 month ago - MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies - GlobeNewsWire